SCPH - SCファ―マシュ―ティカルズ (scPharmaceuticals Inc.) SCファ―マシュ―ティカルズ

 SCPHのチャート


 SCPHの企業情報

symbol SCPH
会社名 scPharmaceuticals Inc (SCファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医療機器_医療用品_ディストリビュ―タ―   医療関連(Health Care)
概要 事業概要 scファーマスーティカルズ(scPharmaceuticals Inc.)は生物医薬品企業である。同社は皮下送達用医薬品の開発に従事する。同社は標準の医療用接着剤を使用して身体に取り付けられる小型ポンプであるsc2Wear Infusorを提供する。sc2Wear Infusorは静脈内点滴と同様に、薬物を体内に注入する。同社の製品はsc2Wear Infusorを介して皮下投与される。同社のパイプラインプログラムには急性期治療以外の心不全患者の利尿用sc2Wear Infusorを介して提供されるフロセミドの皮下製剤を含むscFurosemideリード製品候補であるFuroscixを含む。同社はFuroscixの2つの臨床試験、4つの臨床試験、12のヒト因子試験、およびグラム陽性およびグラム陰性菌による感染の治療用静脈内使用の抗生物質scCeftriaxoneを完了した。   SCファ―マシュ―ティカルズは米国の医薬品企業。主に治療法の開発、患者に対するケアの高度化、医療費の削減につながる可能性のある医薬品の開発・商業化に従事する。同社の製品候補には心不全など心臓疾患に対する治療薬、また感染症などの治療薬を含む。本社所在地はマサチュ―セッツ州バ―リントン。   scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that are designed to reduce healthcare costs and improve health outcomes. The Company develops, internally and through strategic partnerships, innovative products and solutions that aim to expand and advance the outpatient care of select acute conditions. The Company's lead programs focus on the subcutaneous, self-administration of IV-strength treatments in heart failure and infectious disease. scPharmaceuticals is headquartered in Burlington, MA.
本社所在地 2400 District Avenue Suite 310 Burlington MA 01803 USA
代表者氏名 John H. Tucker ジョンH.タッカー
代表者役職名 President Chief Executive Officer Director 社長兼最高経営責任者(CEO)
電話番号 +1 617-517-0730
設立年月日 41306
市場名 NASDAQ National Market System
ipoyear 2017年
従業員数
url www.scpharmaceuticals.com
nasdaq_url https://www.nasdaq.com/symbol/scph
adr_tso
EBITDA EBITDA(百万ドル) -30.38400
終値(lastsale) 5.43
時価総額(marketcap) 100831239.27
時価総額 時価総額(百万ドル) 82.07626
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) -7.30674
当期純利益 当期純利益(百万ドル) -30.95100
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Scpharmaceuticals Inc revenues was not reported. Net loss increased 62% to $18.6M. Higher net loss reflects General and administrative increase from $4.4M to $9.7M (expense) Research and development increase of 27% to $8.9M (expense) Interest expense increase from $132K to $701K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.65 to -$1.00.

 SCPHのテクニカル分析


 SCPHのニュース

   scPharmaceuticals Inc. Presents Late-breaking FREEDOM-HF Study Data at the Heart Failure Society of America Annual Scientific Meeting 2021  2021/09/10 12:00:00 Intrado Digital Media
Data show statistically significant and meaningful reduction in both heart failure-related and overall healthcare costs for patients treated with FUROSCIX® versus a historical comparator group
   scPharmaceuticals to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference  2021/09/01 12:00:00 Intrado Digital Media
BURLINGTON, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, president & chief executive officer, is scheduled to present at the H.C. Wainwright 23 rd Annual Global Investment Conference, being held virtually September 13-15, 2021.
   scPharmaceuticals EPS misses by $0.06  2021/08/11 11:26:38 Seeking Alpha
   scPharmaceuticals Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update  2021/08/11 11:00:00 Intrado Digital Media
Received minutes from Type C meeting with the FDA confirming alignment on path toward resubmission of FUROSCIX ® NDA; no additional clinical data or device modifications required at this time; on track for resubmission in Q4
   scPharmaceuticals Inc Shares Close the Day 12.3% Lower - Daily Wrap  2021/07/16 02:04:50 Kwhen Finance
scPharmaceuticals Inc (SCPH) shares closed today 12.3% lower than it did at the end of yesterday. The stock is currently up 18.5% year-to-date, down 15.2% over the past 12 months, and down 55.5% over the past five years. Today, the Dow Jones Industrial Average rose 0.2%, and the S&P 500 fell 0.3%. Trading Activity Shares traded as high as $6.84 and as low as $5.43 this week.Shares closed 42.9% below its 52-week high and 8.7% above its 52-week low.Trading volume this week was 139.8% higher than the 10-day average and 286.8% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.7. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price lags the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -336.7% The company's stock price performance over the past 12 months lags the peer average by 31.2% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   scPharmaceuticals Inc. Announces Receipt of Written Minutes from Type C Meeting with the FDA Regarding Development of FUROSCIX  2021/07/01 12:00:00 Wallstreet:Online
FDA and Company in alignment on the path forward No additional clinical data or device modifications required at this time FUROSCIX NDA resubmission targeted for Q4 2021 BURLINGTON, Mass., July 01, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery
   scPharmaceuticals Inc. Announces Receipt of Written Minutes from Type C Meeting with the FDA Regarding Development of FUROSCIX®  2021/07/01 12:00:00 Intrado Digital Media
FDA and Company in alignment on the path forward
   scPharmaceuticals to Present at the Jefferies Virtual Healthcare Conference  2021/05/19 00:00:00 BioSpace
scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, president & chief executive officer, is scheduled to present at the Jefferies Virtual Healthcare Conference on Wednesday, June 2 at 3:30 EDT.
   scPharmaceuticals: The Third Time''s A Charm  2021/05/12 13:11:45 Seeking Alpha
   Zacks: Brokerages Anticipate scPharmaceuticals Inc. (NASDAQ:SCPH) to Post -$0.31 EPS  2021/05/12 12:50:41 Transcript Daily
Equities research analysts expect scPharmaceuticals Inc. (NASDAQ:SCPH) to report earnings of ($0.31) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for scPharmaceuticals earnings, with estimates ranging from ($0.31) to ($0.30). scPharmaceuticals reported earnings per share of ($0.35) during the same quarter last year, which would suggest a []
   scPharmaceuticals to Present at the Jefferies Virtual Healthcare Conference  2021/05/19 00:00:00 BioSpace
scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, president & chief executive officer, is scheduled to present at the Jefferies Virtual Healthcare Conference on Wednesday, June 2 at 3:30 EDT.
   scPharmaceuticals: The Third Time''s A Charm  2021/05/12 13:11:45 Seeking Alpha
   Zacks: Brokerages Anticipate scPharmaceuticals Inc. (NASDAQ:SCPH) to Post -$0.31 EPS  2021/05/12 12:50:41 Transcript Daily
Equities research analysts expect scPharmaceuticals Inc. (NASDAQ:SCPH) to report earnings of ($0.31) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for scPharmaceuticals earnings, with estimates ranging from ($0.31) to ($0.30). scPharmaceuticals reported earnings per share of ($0.35) during the same quarter last year, which would suggest a []
   scPharmaceuticals EPS misses by $0.05  2021/05/12 12:25:19 Seeking Alpha
   scPharmaceuticals Inc. Reports First Quarter 2021 Financial Results and Provides Business Update  2021/05/12 00:00:00 BioSpace
scPharmaceuticals Inc., a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, announced financial results for the first quarter ended March 31, 2021 and provided a business update.

 関連キーワード  (医療機器_医療用品_ディストリビュ―タ― 米国株 SCファ―マシュ―ティカルズ SCPH scPharmaceuticals Inc.)

医療で使われる機器のこと。レントゲン装置やからだの断面を画像化できるMRI(磁気共鳴画像)装置など高機能機器を含め数多くの種類がある。医療現場で使われるため、正確で精密である点などが求められる。医療機器への需要は着実に高まっており、電機メーカーなどからの進出も進んでいる。

 twitter  (公式ツイッターやCEOツイッターなど)